BioElectronics Corporation (BIEL)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioElectronics Corporation (BIEL) with AI Score 53/100 (Hold). BioElectronics Corporation develops and sells wearable neuromodulation devices for pain management and neurological conditions. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026BioElectronics Corporation (BIEL) Healthcare & Pipeline Overview
BioElectronics Corporation is an electroceutical company focused on developing and marketing wearable neuromodulation devices for pain management and neurological conditions. Its product portfolio, including ActiPatch and Allay, caters to both human and animal healthcare markets, offering non-pharmaceutical alternatives for pain relief and tissue healing.
Investment Thesis
BioElectronics Corporation presents a compelling investment case centered on its innovative electroceutical devices and expanding market reach. The company's focus on non-pharmaceutical pain management solutions aligns with the increasing demand for safer, non-addictive therapies. With a gross margin of 73.3%, BioElectronics demonstrates strong potential for profitability as it scales its operations. Key growth catalysts include expanding distribution channels, securing regulatory approvals for new products, and increasing market penetration in both human and animal healthcare segments. However, the company's negative profit margin of -187.6% and reliance on OTC markets pose significant risks. Investors should closely monitor the company's ability to achieve profitability and navigate the challenges associated with OTC trading.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 73.3% indicates strong potential for profitability as the company scales its operations.
- The company operates in the electroceuticals market, a growing sector driven by demand for non-pharmaceutical pain management solutions.
- Product portfolio includes ActiPatch, a recognized therapy for musculoskeletal pain, providing a foundation for revenue generation.
- The company distributes its products through multiple channels, including wholesale distributors, hospitals, clinics, and direct to consumers, ensuring broad market access.
- Beta of 2.03 suggests higher volatility compared to the overall market.
Competitors & Peers
Strengths
- Proprietary neuromodulation technology
- Established brand recognition for ActiPatch
- Diverse product portfolio targeting multiple pain conditions
- Distribution network across wholesale, hospitals, clinics, and direct-to-consumer channels
Weaknesses
- Negative profit margin
- Reliance on OTC markets
- Limited financial resources for marketing and R&D
- Dependence on a small number of key products
Catalysts
- Upcoming: Potential regulatory approvals for new products in development.
- Ongoing: Expansion of distribution channels into new geographic markets.
- Ongoing: Increasing adoption of electroceutical devices for pain management.
- Ongoing: Strategic partnerships with established medical device companies.
Risks
- Potential: Competition from established medical device companies.
- Potential: Regulatory hurdles and compliance requirements.
- Ongoing: Patent expiration and intellectual property risks.
- Ongoing: Negative profit margin and limited financial resources.
- Potential: Economic downturn affecting healthcare spending.
Growth Opportunities
- Expansion into New Therapeutic Areas: BioElectronics has the opportunity to expand its product line to address additional therapeutic areas beyond pain management, such as neurological disorders and wound healing. The market for neurological disorder treatments is substantial, with a global market size estimated at billions of dollars. By leveraging its existing neuromodulation technology, BioElectronics can develop new devices targeting these conditions, potentially increasing its revenue streams and market share. Timeline: 2-3 years for product development and regulatory approval.
- Geographic Market Expansion: BioElectronics can pursue growth by expanding its market presence into new geographic regions, particularly in developing countries where access to traditional pain management therapies may be limited. These markets often have less stringent regulatory requirements, allowing for faster market entry. The global market for medical devices is expanding rapidly, driven by increasing healthcare expenditure and aging populations. Timeline: 1-2 years for market entry and distribution setup.
- Strategic Partnerships and Acquisitions: BioElectronics can accelerate its growth through strategic partnerships and acquisitions. Collaborating with established medical device companies or acquiring complementary technologies can enhance its product portfolio and market reach. The medical device industry is characterized by consolidation, with larger companies acquiring smaller, innovative firms. Timeline: Ongoing, with potential deals occurring within the next 1-3 years.
- Direct-to-Consumer Marketing and E-commerce: BioElectronics can increase sales and brand awareness by investing in direct-to-consumer marketing and expanding its e-commerce presence. Online sales of medical devices are growing rapidly, driven by increasing consumer adoption of e-commerce and the convenience of online shopping. By targeting consumers directly, BioElectronics can bypass traditional distribution channels and increase its profit margins. Timeline: 6-12 months for implementation and optimization.
- Veterinary Market Expansion: BioElectronics can further penetrate the veterinary market with its HealFast product line. The market for animal healthcare products is growing, driven by increasing pet ownership and rising awareness of animal health and welfare. By expanding its distribution channels and marketing efforts in the veterinary market, BioElectronics can increase sales and establish itself as a leading provider of drug-free therapies for animals. Timeline: 1-2 years for market expansion and product development.
Opportunities
- Expansion into new therapeutic areas
- Geographic market expansion
- Strategic partnerships and acquisitions
- Direct-to-consumer marketing and e-commerce growth
Threats
- Competition from established medical device companies
- Regulatory hurdles and compliance requirements
- Patent expiration and intellectual property risks
- Economic downturn affecting healthcare spending
Competitive Advantages
- Proprietary neuromodulation technology.
- Established brand recognition for ActiPatch.
- Distribution network across multiple channels.
- Focus on non-pharmaceutical pain management.
About BIEL
BioElectronics Corporation, established in 2000 and headquartered in Frederick, Maryland, is an electroceutical company specializing in the development and commercialization of wearable neuromodulation devices. These devices are designed to alleviate pain and improve the quality of life for individuals suffering from neurological diseases and musculoskeletal conditions. The company's flagship product, ActiPatch, is a widely recognized therapy for musculoskeletal pain. Other key products include Allay, specifically designed for menstrual pain relief; Smart Insole, targeting heel pain; RecoveryRx, a pain management solution for medical professionals; and HealFast, a drug-free therapy for animals, addressing pain, swelling, and injuries in horses, cats, and dogs. BioElectronics distributes its products through a network of wholesale distributors, hospitals, clinics, and directly to consumers, ensuring broad market access. The company's focus on non-invasive, drug-free pain management positions it within the growing electroceuticals market, offering alternatives to traditional pharmaceutical interventions.
What They Do
- Develops wearable neuromodulation devices.
- Offers ActiPatch for musculoskeletal pain therapy.
- Provides Allay for menstrual pain therapy.
- Markets Smart Insole for heel pain therapy.
- Sells RecoveryRx for pain management in medical settings.
- Distributes HealFast for pain relief in animals.
Business Model
- Develops and manufactures wearable neuromodulation devices.
- Sells products through wholesale distributors, hospitals, and clinics.
- Offers direct-to-consumer sales through online channels.
Industry Context
BioElectronics Corporation operates within the medical device industry, specifically in the electroceuticals sub-segment. This market is experiencing growth due to increasing demand for non-invasive, drug-free pain management solutions. The competitive landscape includes companies like ADMT, AIMLF, BGXX, CHMMF, and GVDI, some of which offer similar neuromodulation devices or alternative pain management therapies. The electroceuticals market is projected to grow as technological advancements and regulatory support increase, driving adoption of these innovative therapies. BioElectronics is positioned to capitalize on this trend with its established product line and distribution network.
Key Customers
- Individuals suffering from musculoskeletal pain.
- Women experiencing menstrual pain.
- Medical professionals seeking pain management solutions.
- Pet owners and veterinarians treating animal injuries.
Financials
Chart & Info
BioElectronics Corporation (BIEL) stock price: Price data unavailable
Latest News
No recent news available for BIEL.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIEL.
Price Targets
Wall Street price target analysis for BIEL.
MoonshotScore
What does this score mean?
The MoonshotScore rates BIEL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kelly A. Whelan
Unknown
Information about Kelly A. Whelan's background is not available in the provided context. Therefore, a detailed biography cannot be provided. Further research would be needed to gather information on their career history, education, and previous roles.
Track Record: Information about Kelly A. Whelan's track record is not available in the provided context. Therefore, key achievements, strategic decisions, and company milestones under their leadership cannot be provided. Further research would be needed to gather this information.
BIEL OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BioElectronics Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Higher price volatility
- Lower trading volume
- Potential for fraud or manipulation
- Limited regulatory oversight
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's risk factors and potential liabilities.
- Check for any red flags or warning signs.
- Consult with a financial advisor before investing.
- Established business operations since 2000.
- Proprietary neuromodulation technology.
- Product distribution through multiple channels.
- Focus on non-pharmaceutical pain management.
Common Questions About BIEL
What does BioElectronics Corporation do?
BioElectronics Corporation is an electroceutical company that develops, manufactures, and markets wearable neuromodulation devices. These devices are designed to provide non-invasive, drug-free pain relief for various conditions, including musculoskeletal pain, menstrual pain, and heel pain. The company's product line includes ActiPatch, Allay, Smart Insole, RecoveryRx, and HealFast, targeting both human and animal healthcare markets. BioElectronics sells its products through wholesale distributors, hospitals, clinics, and directly to consumers, offering an alternative to traditional pharmaceutical interventions for pain management.
What do analysts say about BIEL stock?
As of 2026-03-16, there is no available analyst coverage for BioElectronics Corporation (BIEL). The company's OTC listing and limited financial disclosure may contribute to the lack of analyst coverage. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, may not be readily available or reliable due to the company's financial situation.
What are the main risks for BIEL?
BioElectronics Corporation faces several risks, including competition from established medical device companies, regulatory hurdles and compliance requirements, patent expiration and intellectual property risks, negative profit margin and limited financial resources, and potential economic downturn affecting healthcare spending. The company's reliance on OTC markets also poses additional risks, such as limited financial disclosure, higher price volatility, and lower trading volume. Investors should carefully consider these risks before investing in BIEL.
What are the key factors to evaluate for BIEL?
BioElectronics Corporation (BIEL) currently holds an AI score of 53/100, indicating moderate score. Key strength: Proprietary neuromodulation technology. Primary risk to monitor: Potential: Competition from established medical device companies.. This is not financial advice.
How frequently does BIEL data refresh on this page?
BIEL prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BIEL's recent stock price performance?
Recent price movement in BioElectronics Corporation (BIEL) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary neuromodulation technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BIEL overvalued or undervalued right now?
Determining whether BioElectronics Corporation (BIEL) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BIEL?
Before investing in BioElectronics Corporation (BIEL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data based on available information and may not be comprehensive.